학술논문
A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation
Document Type
Article
Author
Source
Transplantation; May 2003, Vol. 75 Issue: 9 p1501-1505, 5p
Subject
Language
ISSN
00411337; 15346080
Abstract
For stable kidney-transplant recipients receiving triple drug therapy with cyclosporine (CsA), prednisone, and mycophenolate mofetil (MMF), it remains unclear what is the optimal dose of CsA beyond the first 6 to 12 months after transplantation. Complete CsA withdrawal has been associated with a significant incidence of acute rejection and, in some studies, chronic rejection as well.